Coya Therapeutics appoints Dr. Fred Grossman as President and CMO; compensation terms disclosed

Coya Therapeutics, Inc.

Base salary of $450,000/year; annual bonus target of 40% of base salary based on company/individual performance.
Two option grants of 74,069 each (start date and Jan 2024) vesting over 3 years; additional equity possible.
Severance: 9 months base salary plus 9 months accelerated vesting if terminated without cause or resigns for good reason.
Employment effective July 17, 2023; initial term 2 years with auto-renewal.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Fred Grossman

President and Chief Medical Officer

COYA · Coya Therapeutics, Inc.

Effective: 2023-07-17
Filed: July 14, 2023, 7:59 PM ET

Dr. Fred Grossman, who will assume the role of President and Chief Medical Officer as of July 17, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Fred Grossman was appointed as President and Chief Medical Officer at Coya Therapeutics, Inc..

Action: appointed
Role: President and Chief Medical Officer

Exact text from the filing

Dr. Fred Grossman, who will assume the role of President and Chief Medical Officer as of July 17, 2023

View on SEC.gov

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-187328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.